Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Auchus, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auchus, A. P.
Related Collections
Right arrow All Cerebrovascular disease/Stroke
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow All Cognitive Disorders/Dementia
Right arrow Alzheimer's disease
Right arrow Vascular dementia
NEUROLOGY 2007;69:448-458
© 2007 American Academy of Neurology

Galantamine treatment of vascular dementia

A randomized trial

A. P. Auchus, MD, H. R. Brashear, MD, S. Salloway, MD, A. D. Korczyn, MD, P. P. De Deyn, MD, C. Gassmann-Mayer, PhD For the GAL-INT-26 Study Group

From the Department of Neurology, University of Tennessee Health Science Center, and Memphis VAMC, Memphis, TN (A.P.A.); Johnson & Johnson Pharmaceutical Research and Development, L.L.C., La Jolla, CA (H.R.B., C.G.-M.); Director of Neurology and The Memory Disorders Program, Butler Hospital, Providence, RI (S.S.); Sieratzki Chair of Neurology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel (A.D.K.); and Department of Neurology, General Hospital Middelheim, University of Antwerp, Antwerp, Belgium (P.P.D.D.).

Address correspondence and reprint requests to Dr. Alexander P. Auchus, University of Tennessee Health Science Center, Department of Neurology, 855 Monroe Avenue, Suite 415, Memphis, TN 38163 aauchus{at}utmem.edu

Background: To evaluate efficacy and safety of galantamine for patients with vascular dementia (VaD).

Methods: In this multinational, randomized, double-blind, placebo-controlled, parallel-group clinical trial, 788 patients with probable VaD who also satisfied strict centrally read MRI criteria were randomized to receive galantamine or placebo. Efficacy was evaluated using measures of cognition, daily function, and behavior. The primary efficacy measures were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog/11) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) total score. Secondary outcomes included the Clinician's Interview Based on Impression of Change-Plus Caregiver Input (CIBIC-plus), Neuropsychiatric Inventory, and EXIT-25 for assessment of executive functioning. Safety and tolerability were also monitored.

Results: Patients treated with galantamine had a greater improvement in ADAS-cog/11 after 26 weeks compared with placebo (–1.8 vs –0.3; p < 0.001). There was no difference between galantamine and placebo at week 26 on the ADCS-ADL score (0.7 vs 1.3; p = 0.783). Improvement in global functioning measured by the CIBIC-plus associated with galantamine approached significance (p = 0.069). A difference between treatment groups for EXIT-25 favoring galantamine was detected (p = 0.041). Safety data revealed that 13% of galantamine and 6% of placebo patients discontinued treatment because of adverse events.

Conclusions: Significance was not reached for both co-primary endpoints. Galantamine was effective for improving cognition, including executive function, in patients with vascular dementia, with good safety and tolerability. However, improvement in activities of daily living with galantamine was similar to that observed with placebo.

Disclosures: Dr. Auchus has received research grant support exceeding $10,000 from Johnson & Johnson, Pfizer/Eisai, Neurochem, and Avanir. He has served as a consultant for Johnson & Johnson, Pfizer, Avanir, and Forest and has received honoraria from Pfizer, Forest, and Novartis. Drs. Brashear and Gassmann-Mayer are full employees of Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Dr. Gassmann-Mayer conducted the statistical analysis. Dr. Salloway has received research support and honoraria and has served as a consultant for Johnson & Johnson, Eisai, Pfizer, Forest, and Myriad Pharmaceuticals. He receives research support from Elan, Neurochem, Voyager, and the National Institutes of Health. He serves as a consultant for Merck and Sanofi-Aventis. Dr. Korczyn has not reported any disclosures. Dr. De Deyn has been a consultant for, and has served on advisory boards for, Johnson & Johnson, Bristol-Myers Squibb, Novartis, and AstraZeneca. He is a member of speakers' bureaus for Johnson & Johnson, Bristol-Myers Squibb, and Lundbeck. He has received clinical and/or preclinical study grants from Johnson & Johnson and Lundbeck.

Received February 23, 2006. Accepted in final form March 2, 2007.




This article has been cited by other articles:


Home page
 StrokeHome page
P. B. Gorelick and J. V. Bowler
Advances in Vascular Cognitive Impairment 2007
Stroke, February 1, 2008; 39(2): 279 - 282.
[Full Text] [PDF]

Home page
 JWatch GeneralHome page
Cholinesterase Inhibitors for Dementia More Studies, Similar Results
Journal Watch (General), August 9, 2007; 2007(809): 5 - 5.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.